mirabegron + rifampin

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pharmacokinetics of YM178

Conditions

Pharmacokinetics of YM178

Trial Timeline

Oct 1, 2008 → Dec 1, 2008

About mirabegron + rifampin

mirabegron + rifampin is a phase 1 stage product being developed by Astellas Pharma for Pharmacokinetics of YM178. The current trial status is completed. This product is registered under clinical trial identifier NCT00776516. Target conditions include Pharmacokinetics of YM178.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00776516Phase 1Completed

Competing Products

20 competing products in Pharmacokinetics of YM178

See all competitors